[6-K] BioNTech SE American Depositary Share Current Report (Foreign Issuer)
Filing: On August 4, 2025, BioNTech SE filed a Form 6-K reporting a development update and its financial results for the three and six months ended June 30, 2025.
Exhibit: The filing states that the interim condensed consolidated financial statements and the operating and financial review and prospects for the three and six months ended June 30, 2025 are attached as Exhibit 99.1 and are deemed filed under Section 18 of the Exchange Act.
Signatures: The report is signed by Ram贸n Zapata-Gomez, Chief Financial Officer, and Dr. Sierk Poetting, Chief Operating Officer, dated August 4, 2025. The Form 6-K body contains no financial line-item figures; readers are referred to Exhibit 99.1 for detailed results.
Deposito: Il 4 agosto 2025 BioNTech SE ha presentato un Form 6-K con un aggiornamento sullo sviluppo e i risultati finanziari per i tre e i sei mesi chiusi al 30 giugno 2025.
Allegato: La comunicazione indica che il bilancio consolidato intermedio abbreviato e la relazione sulla gestione e sulle prospettive operative e finanziarie per i tre e i sei mesi chiusi al 30 giugno 2025 sono allegati come Exhibit 99.1 e sono considerati depositati ai sensi della Sezione 18 dell'Exchange Act.
Firme: Il rapporto 猫 firmato da Ram贸n Zapata-Gomez, Chief Financial Officer, e Dr. Sierk Poetting, Chief Operating Officer, con data 4 agosto 2025. Il corpo del Form 6鈥慘 non contiene importi finanziari per voci di bilancio; per i risultati dettagliati si rimanda all'Exhibit 99.1.
笔谤别蝉别苍迟补肠颈贸苍: El 4 de agosto de 2025 BioNTech SE present贸 un Form 6-K con una actualizaci贸n de desarrollo y los resultados financieros correspondientes a los tres y seis meses terminados el 30 de junio de 2025.
Anexo: La presentaci贸n indica que los estados financieros consolidados intermedios condensados y la secci贸n de revisi贸n operativa y financiera y perspectivas para los tres y seis meses terminados el 30 de junio de 2025 se adjuntan como Exhibit 99.1 y se consideran presentados conforme a la Secci贸n 18 del Exchange Act.
Firmas: El informe est谩 firmado por Ram贸n Zapata-Gomez, Chief Financial Officer, y Dr. Sierk Poetting, Chief Operating Officer, con fecha 4 de agosto de 2025. El cuerpo del Form 6-K no incluye cifras detalladas por partidas financieras; para los resultados completos consulte el Exhibit 99.1.
鞝涤稖: 2025雲� 8鞗� 4鞚� BioNTech SE電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈 霃欖晥鞚� 臧滊皽 鞐呺嵃鞚错姼鞕� 鞛鞁れ爜鞚� 氤搓碃頃� Form 6-K毳� 鞝滌稖頄堨姷雼堧嫟.
觳秬氍胳劀: 鞝滌稖靹滌棎電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈鞐� 雽�頃� 欷戧皠 鞐瓣舶鞖旍暯 鞛鞝滍憸 氚� 鞓侅梾路鞛 瓴�韱犾檧 鞝勲鞚� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅� Exchange Act鞚� 靹轨厴 18鞐� 霐半澕 鞝滌稖霅� 瓴冹溂搿� 臧勳＜霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
靹滊獏: 鞚� 氤搓碃靹滊姅 Ram贸n Zapata-Gomez 斓滉碃鞛毂呾瀯鞛�(颁贵翱)鞕赌 Dr. Sierk Poetting 斓滉碃鞖挫榿毂呾瀯鞛�(COO)臧� 2025雲� 8鞗� 4鞚检瀽搿� 靹滊獏頄堨姷雼堧嫟. Form 6-K 氤鸽鞐愲姅 臧滊硠 鞛頃 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿�, 靸侅劯頃� 瓴瓣臣電� Exhibit 99.1鞚� 彀胳“頃橃嫓旮� 氚旊瀺雼堧嫟.
D茅p么t : Le 4 ao没t 2025, BioNTech SE a d茅pos茅 un Form 6鈥慘 faisant 茅tat d'une mise 脿 jour sur le d茅veloppement et des r茅sultats financiers pour les trois et six mois clos le 30 juin 2025.
Pi猫ce : Le d茅p么t indique que les 茅tats financiers consolid茅s interm茅diaires condens茅s et la revue op茅rationnelle et financi猫re ainsi que les perspectives pour les trois et six mois clos le 30 juin 2025 sont joints en tant que Exhibit 99.1 et sont r茅put茅s d茅pos茅s en vertu de la Section 18 de l'Exchange Act.
Signatures : Le rapport est sign茅 par Ram贸n Zapata-Gomez, Chief Financial Officer, et Dr. Sierk Poetting, Chief Operating Officer, dat茅 du 4 ao没t 2025. Le corps du Form 6鈥慘 ne contient pas de montants d茅taill茅s par poste ; pour les r茅sultats complets, veuillez consulter la Exhibit 99.1.
Einreichung: Am 4. August 2025 hat BioNTech SE ein Form 6-K eingereicht, das ein Entwicklungs-Update und die Finanzergebnisse f眉r die drei und sechs Monate zum 30. Juni 2025 berichtet.
Anlage: In der Einreichung hei脽t es, dass die verk眉rzten konsolidierten Zwischenfinanzabschl眉sse sowie der Bericht zur operativen und finanziellen Lage und zu den Aussichten f眉r die drei und sechs Monate zum 30. Juni 2025 als Exhibit 99.1 beigef眉gt sind und gem盲脽 Section 18 des Exchange Act als eingereicht gelten.
Unterschriften: Der Bericht ist von Ram贸n Zapata-Gomez, Chief Financial Officer (CFO), und Dr. Sierk Poetting, Chief Operating Officer (COO), unterzeichnet und datiert mit dem 4. August 2025. Der Text des Form 6-K enth盲lt keine einzelnen finanziellen Positionen; f眉r detaillierte Ergebnisse wird auf Exhibit 99.1 verwiesen.
- Interim financial statements and operating review filed as Exhibit 99.1
- Report signed by CFO and COO
- Filing dated and formally incorporated under Section 18 of the Exchange Act
- No financial line-item figures or metrics are provided in the Form 6-K body
Insights
TL;DR: Routine Form 6-K filing; interim financials and management review attached as Exhibit 99.1鈥攏o figures included in the 6-K body.
BioNTech's Form 6-K notifies investors that the company's interim condensed consolidated financial statements and operating and financial review for Q2 and the six months ended June 30, 2025 are filed as Exhibit 99.1. The filing itself is procedural and does not present standalone financial metrics in the body, so material analysis requires review of Exhibit 99.1. Signatures from the CFO and COO indicate standard executive attestation.
TL;DR: Governance disclosure appears standard: timely submission and executive sign-off; substantive details are contained in the attached exhibit.
The Form 6-K documents a development update and incorporates the interim financial statements and management's review by reference via Exhibit 99.1. The report is duly signed by the Chief Financial Officer and Chief Operating Officer and dated August 4, 2025. From a governance perspective, the filing meets routine disclosure expectations; investors should examine Exhibit 99.1 for audited or interim figures and forward-looking commentary.
Deposito: Il 4 agosto 2025 BioNTech SE ha presentato un Form 6-K con un aggiornamento sullo sviluppo e i risultati finanziari per i tre e i sei mesi chiusi al 30 giugno 2025.
Allegato: La comunicazione indica che il bilancio consolidato intermedio abbreviato e la relazione sulla gestione e sulle prospettive operative e finanziarie per i tre e i sei mesi chiusi al 30 giugno 2025 sono allegati come Exhibit 99.1 e sono considerati depositati ai sensi della Sezione 18 dell'Exchange Act.
Firme: Il rapporto 猫 firmato da Ram贸n Zapata-Gomez, Chief Financial Officer, e Dr. Sierk Poetting, Chief Operating Officer, con data 4 agosto 2025. Il corpo del Form 6鈥慘 non contiene importi finanziari per voci di bilancio; per i risultati dettagliati si rimanda all'Exhibit 99.1.
笔谤别蝉别苍迟补肠颈贸苍: El 4 de agosto de 2025 BioNTech SE present贸 un Form 6-K con una actualizaci贸n de desarrollo y los resultados financieros correspondientes a los tres y seis meses terminados el 30 de junio de 2025.
Anexo: La presentaci贸n indica que los estados financieros consolidados intermedios condensados y la secci贸n de revisi贸n operativa y financiera y perspectivas para los tres y seis meses terminados el 30 de junio de 2025 se adjuntan como Exhibit 99.1 y se consideran presentados conforme a la Secci贸n 18 del Exchange Act.
Firmas: El informe est谩 firmado por Ram贸n Zapata-Gomez, Chief Financial Officer, y Dr. Sierk Poetting, Chief Operating Officer, con fecha 4 de agosto de 2025. El cuerpo del Form 6-K no incluye cifras detalladas por partidas financieras; para los resultados completos consulte el Exhibit 99.1.
鞝涤稖: 2025雲� 8鞗� 4鞚� BioNTech SE電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈 霃欖晥鞚� 臧滊皽 鞐呺嵃鞚错姼鞕� 鞛鞁れ爜鞚� 氤搓碃頃� Form 6-K毳� 鞝滌稖頄堨姷雼堧嫟.
觳秬氍胳劀: 鞝滌稖靹滌棎電� 2025雲� 6鞗� 30鞚茧 膦呺霅� 3臧滌洈 氚� 6臧滌洈鞐� 雽�頃� 欷戧皠 鞐瓣舶鞖旍暯 鞛鞝滍憸 氚� 鞓侅梾路鞛 瓴�韱犾檧 鞝勲鞚� Exhibit 99.1搿� 觳秬霅橃柎 鞛堨溂氅� Exchange Act鞚� 靹轨厴 18鞐� 霐半澕 鞝滌稖霅� 瓴冹溂搿� 臧勳＜霅滊嫟瓿� 氇呾嫓霅橃柎 鞛堨姷雼堧嫟.
靹滊獏: 鞚� 氤搓碃靹滊姅 Ram贸n Zapata-Gomez 斓滉碃鞛毂呾瀯鞛�(颁贵翱)鞕赌 Dr. Sierk Poetting 斓滉碃鞖挫榿毂呾瀯鞛�(COO)臧� 2025雲� 8鞗� 4鞚检瀽搿� 靹滊獏頄堨姷雼堧嫟. Form 6-K 氤鸽鞐愲姅 臧滊硠 鞛頃 靾橃箻臧� 韽暔霅橃柎 鞛堨 鞎婌溂氙�搿�, 靸侅劯頃� 瓴瓣臣電� Exhibit 99.1鞚� 彀胳“頃橃嫓旮� 氚旊瀺雼堧嫟.
D茅p么t : Le 4 ao没t 2025, BioNTech SE a d茅pos茅 un Form 6鈥慘 faisant 茅tat d'une mise 脿 jour sur le d茅veloppement et des r茅sultats financiers pour les trois et six mois clos le 30 juin 2025.
Pi猫ce : Le d茅p么t indique que les 茅tats financiers consolid茅s interm茅diaires condens茅s et la revue op茅rationnelle et financi猫re ainsi que les perspectives pour les trois et six mois clos le 30 juin 2025 sont joints en tant que Exhibit 99.1 et sont r茅put茅s d茅pos茅s en vertu de la Section 18 de l'Exchange Act.
Signatures : Le rapport est sign茅 par Ram贸n Zapata-Gomez, Chief Financial Officer, et Dr. Sierk Poetting, Chief Operating Officer, dat茅 du 4 ao没t 2025. Le corps du Form 6鈥慘 ne contient pas de montants d茅taill茅s par poste ; pour les r茅sultats complets, veuillez consulter la Exhibit 99.1.
Einreichung: Am 4. August 2025 hat BioNTech SE ein Form 6-K eingereicht, das ein Entwicklungs-Update und die Finanzergebnisse f眉r die drei und sechs Monate zum 30. Juni 2025 berichtet.
Anlage: In der Einreichung hei脽t es, dass die verk眉rzten konsolidierten Zwischenfinanzabschl眉sse sowie der Bericht zur operativen und finanziellen Lage und zu den Aussichten f眉r die drei und sechs Monate zum 30. Juni 2025 als Exhibit 99.1 beigef眉gt sind und gem盲脽 Section 18 des Exchange Act als eingereicht gelten.
Unterschriften: Der Bericht ist von Ram贸n Zapata-Gomez, Chief Financial Officer (CFO), und Dr. Sierk Poetting, Chief Operating Officer (COO), unterzeichnet und datiert mit dem 4. August 2025. Der Text des Form 6-K enth盲lt keine einzelnen finanziellen Positionen; f眉r detaillierte Ergebnisse wird auf Exhibit 99.1 verwiesen.
FAQ
What did BioNTech (BNTX) file on August 4, 2025?
Where are the interim financial statements for Q2 2025 included?
Does the Form 6-K include detailed financial numbers?
Who signed the Form 6-K for BioNTech?
What date is shown on the filing?
